Obstetric Anesthesia Digest · 2022 · 14 citations · 0 references
MedicinePediatricsPharmacotherapyMolecular VirologyPediatric Infectious DiseasesVirologyAntiviral PharmacologyAntiviral TherapyCare Of Premature InfantsInfant Infectious DiseasesPreterm Infant CareAnimal Disease ModelsGestational Age At BirthInfant Infection PreventionLate Preterm BirthMonoclonal Antibody InteractionsProduct Safety ProfileProtection Against Early-life InfectionRespiratory Syncytial Virus Prophylaxis
( N Engl J Med . 2022;386:837–846. doi: 10.1056/NEJMoa2110275) Infants experience medically attended illness and hospitalization at elevated rates from respiratory syncytial virus (RSV) infection. As a monoclonal antibody with an extended half-life, Nirsevimab (N) is an emerging treatment that binds to the RSV fusion protein and has enhanced inhibitory potency for RSV in cell-culture and animal models over Palivizumab. Preterm (29 to <35 wk gestational age birth) infants receiving a single dose of N before RSV season showed 70.1% efficacy at protection against RSV with a favorable safety profile. The safety and efficacy of N in late-preterm and term infants entering their first RSV season is investigated in this phase 3 trial.